On Thursday, Alcatel Lucent SA (ADR) (NYSE:ALU)’s shares declined -1.10% to $3.58.
Alcatel-Lucent ( ALU) has launched a new device for residential and business use that will allow operators to accelerate the deployment of ultra-broadband access in order to meet ever-growing demand for faster data speeds in homes and the workplace.
The Alcatel-Lucent G.fast residential gateway is a simple, plug-and-play device that will eliminate the need for operators’ engineers to have to enter a customer’s premises to install, thanks to its use of the G.fast standard and application of existing telephone lines to extend fiber-like data speeds into the home.
With the number of connected devices predictable to reach 50-100 billion by 20201, the demand for more bandwidth and faster broadband speeds has never been greater. Fiber-to-the-home and G.fast technologies allow operators to bring gigabit broadband speeds to premises. However, maintaining those speeds inside a building can be more difficult with legacy home networks, poor WiFi speeds and reliability issues limiting how fast and how much data consumers can access at any given time. This problem becomes compounded as more devices are added onto the home network.
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The company’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
SunTrust Banks, Inc. (NYSE:STI)’s shares dropped -0.62% to $43.54.
GenSpring Family Offices, an associate of SunTrust Banks, Inc. (STI), GenSpring Family Offices, a leading wealth administration firm for ultra-high net worth families, has named Chris Walters managing director for the West Region. Walters brings more than 25 years of experience to GenSpring, counting a background of building and growing successful wealth administration teams designed to provide best-in-class service to clients.
In this role, Walters will be responsible for business growth throughout the western United States. He will be based in GenSpring’s Costa Mesa, Calif., family office and oversee GenSpring’s Los Angeles and San Francisco family offices.
Walters joins GenSpring from Rabobank, N.A. where he served as executive vice president. In this role, Walters led Rabobank’s private banking, personal trust, asset administration, institutional trust, brokerage, insurance, financial planning and wealth administration solutions. Formerly, Walters served as executive vice president at Citizens Business Bank where he created Citizens Trust. He also has held executive positions at national and international wealth administration firms, counting Atlantic Trust, Citi Bank and Mellon.
Walters is active in the Southern California community, having served on the Board of Directors for a variety of not-for-profit organizations, counting the Orange County Performing Arts Center, South Coast Repertory Theater, the Pacific Symphony and Little League.
SunTrust Banks, Inc. operates as the holding company for SunTrust Bank that provides various financial services in the United States. The company operates in three segments: Consumer Banking and Private Wealth Administration, Wholesale Banking, and Mortgage Banking. The Consumer Banking and Private Wealth Administration segment offers deposits, home equity lines and loans, credit lines, indirect auto loans, student loans, bank cards, and other lending products, in addition to various services. This segment also provides wealth administration products and professional services, counting brokerage, professional investment administration, and trust services; and family office solutions.
At the end of Thursday’s trade, Kite Pharma Inc (NASDAQ:KITE)‘s shares surged 2.47% to $65.07.
Kite Pharma, Inc. (KITE) and bluebird bio, Inc. (BLUE) declared that they have reached a partnershipagreement to co-develop and co-commercialize second generation T cell receptor (TCR) product candidates directed against the human papillomavirus type 16 E6 (HPV-16 E6) oncoprotein incorporating gene editing and lentiviral technologies. bluebird bio has a platform comprised of lentiviral gene delivery and gene editing capabilities, with a focus on rare diseases and cancer immunotherapies. Kite has a broad existing pipeline of TCR product candidates and will continue to develop its existing and wholly-owned TCR programs directed against high-risk HPV, which are unaffected by this collaboration, counting HPV-16 E6 TCR, presently in a Phase I study, and HPV-16 E7 TCR. The partnership brings together the powerful technologies and capabilities of these two leading immunotherapy companies.
Under the terms of the agreement, both companies will jointly develop and commercialize second generation TCR product candidates directed against the HPV-16 E6 oncoprotein, incorporating gene editing to efficiently modify certain genes to enhance T cell function. In addition, the companies will explore using lentiviral vectors to optimize delivery of HPV-16 E6 TCRs into patient T cells.
Kite will lead the program in the U.S., and bluebird bio will have the option to lead the program in the European Union. Both companies will share overall costs, counting research and development and sales and marketing expenses, and profits will be equally split between the companies. Additionally, Kite will have a co-promotion option in the European Union, and bluebird will have a co-promotion option in the U.S.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers.
Vivint Solar Inc (NYSE:VSLR), ended its Thursday’s trading session with -6.17% loss, and closed at $10.94.
Vivint Solar Inc (VSLR) declared plans to collaborate with Blackstone to provide clean, efficient solar energy to Blackstone’s portfolio of commercial and industrial properties.
Vivint Solar recently closed its first solar commercial and industrial investment fund that will enable the company to expand its solar energy offerings to commercial and industrial businesses across the U.S. Blackstone, a premier investment and advisory firm specializing in private equity, credit and hedge fund investment strategies, presently maintains in its portfolio a vast assortment of commercial and industrial properties.
Vivint Solar, Inc. provides distributed solar energy to residential customers in Arizona, California, Hawaii, Maryland, Massachusetts, New Jersey, New York, and Utah. It installs and owns solar energy systems through long-term customer contracts, such as power purchase agreements and solar energy system leases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
